Thursday, June 2, 2011
U.S. researchers have developed a peptide-based screen for
identifying autoantigens associated with autoimmune diseases.1 The
researchers believe the screen could save time and money compared with other
proteomic screens and plan to use the method to identify autoantigens
associated with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Automating autoantigen discovery
Corresponding author Elledge told SciBX the findings
represent "the first synthetic human proteome and a method to rapidly
Fulmer, T. SciBX 4(22); doi:10.1038/scibx.2011.620
Published online June 2, 2011
H.B. et al. Nat. Biotechnol.; published online May 22, 2011;
Contact: Stephen J. Elledge, Harvard Medical School, Boston, Mass.
COMPANIES AND INSTITUTIONS MENTIONED
Agilent Technologies Inc.
(NYSE:A), Santa Clara, Calif.
Medical School, Boston, Mass.
Institute of Technology, Cambridge, Mass.
of California, San Diego, La Jolla, Calif.